CDC Updates

  • The CDC recommends the Novavax COVID-19 vaccine as a primary two-dose series in adults ages 18 and older.*

    *Select pharmacies will offer the Novavax vaccine: View participating locations

  • The CDC recommends COVID-19 vaccines (Pfizer-BioNTech and Moderna) for everyone ages 6 months and older.*

    *Select pharmacies will be vaccinating children ages 3+: View participating locations

Now offering oral COVID-19 antiviral medications!

Select Harveys Supermarket Pharmacy locations now offer Paxlovid (Pfizer) and Molnupiravir (Merck) to treat mild to moderate COVID-19. Ask your pharmacist for more details!


View participating locations

Now offering the free* COVID-19 vaccine. Schedule your appointment today!

Harveys pharmacies are now able to administer the COVID-19 vaccine. Our pharmacists are experienced in safely providing immunizations, such as flu, shingles and pneumonia. As always, we follow all CDC and state recommended guidelines. Due to the high demand for vaccines, there may be an increased wait time for walk-ins. Schedule your appointment to save time. To save time, download our consent form now

  • *No cost through most insurances or through federal program if not insured. Availability can change quickly based on demand; we understand this might be frustrating. If there are no available appointments at the location you selected, you may choose a nearby location or check back frequently for the next opportunity to schedule your appointment.

COVID Vaccines and Doses

General population

Age group: 6 months - 4 years old*

Number of primary vaccine doses: 3

Interval between 1st and 2nd dose: 3-8 weeks

Interval between 2nd and 3rd dose: 8+ weeks

Number of booster doses: Not currently recommended

More information:
CDC Vaccine Overview

Moderate or severely immunocompromised people

Age group: 6 months - 4 years old*

Number of primary vaccine doses: 3

Interval between 1st and 2nd dose: 3 weeks

Interval between 2nd and 3rd dose: 8+ weeks

Number of booster doses: Not currently recommended

More information:
CDC Vaccine Overview

General population

Age group: 5-11 years old

Number of primary vaccine doses: 2

Interval between 1st and 2nd dose: 3-8 weeks

Number of booster doses: 1

Interval between primary and 1st booster dose: 5+ months

More information:
CDC Vaccine Overview
CDC Booster Overview

Moderate or severely immunocompromised people

Age group: 5-11 years old

Number of primary vaccine doses: 3

Interval between 1st and 2nd dose: 3 weeks

Interval between 2nd and 3rd dose: 4+ weeks

Number of booster doses: 1

Interval between primary and 1st booster dose: 3+ months

More information:
CDC Vaccine Overview
CDC Booster Overview

General population

Number of primary vaccine doses: 2

Interval between 1st and 2nd dose: 3-8 weeks*

Number of booster doses (ages 12-49): 1

Number of booster doses (ages 50+): 2

Interval between primary and 1st booster dose (ages 12+): 5+ months

Interval between 1st booster and 2nd booster dose (ages 50+): 4+ months

More information:
CDC Vaccine Overview
CDC Booster Overview

Moderate or severely immunocompromised people

Number of primary vaccine doses: 3

Interval between 1st and 2nd dose: 3 weeks

Interval between 2nd and 3rd dose: 4+ weeks

Number of booster doses: 2

Interval between primary and 1st booster dose: 3+ months

Interval between 1st booster and 2nd booster dose: 4+ months

More information:
CDC Vaccine Overview
CDC Booster Overview

General population

Age group: 6 months - 5 years old*

Number of primary vaccine doses: 2

Interval between 1st and 2nd dose: 4-8 weeks

Number of booster doses: Not currently recommended

More information:
CDC Vaccine Overview

Moderate or severely immunocompromised people

Age group: 6 months - 5 years old*

Number of primary vaccine doses: 3

Interval between 1st and 2nd dose: 4 weeks

Interval between 2nd and 3rd dose: 4+ weeks

Number of booster doses: Not currently recommended

More information:
CDC Vaccine Overview

*Select pharmacies will be vaccinating children ages 3 through 5. View participating locations.

General population

Age group: 6-11 years old

Number of primary vaccine doses: 2

Interval between 1st and 2nd dose: 4-8 weeks

Number of booster doses: Not currently recommended

More information:
CDC Vaccine Overview

Moderate or severely immunocompromised people

Age group: 6-11 years old

Number of primary vaccine doses: 3

Interval between 1st and 2nd dose: 4 weeks

Interval between 2nd and 3rd dose: 4+ weeks

Number of booster doses: Not currently recommended

More information:
CDC Vaccine Overview

General population

Age group: 12-17 years old

Number of primary vaccine doses: 2

Interval between 1st and 2nd dose: 4-8 weeks

Number of booster doses: Not currently recommended

More information:
CDC Vaccine Overview

Moderate or severely immunocompromised people

Age group: 12-17 years old

Number of primary vaccine doses: 3

Interval between 1st and 2nd dose: 4 weeks

Interval between 2nd and 3rd dose: 4+ weeks

Number of booster doses: Not currently recommended

More information:
CDC Vaccine Overview

General population

Age group: 18+ years old

Number of primary vaccine doses: 2

Interval between 1st and 2nd dose: 4-8 weeks

Number of booster doses (ages 18-49): 1

Number of booster doses (ages 50+): 2

Interval between primary and 1st booster dose (ages 18-49): 5+ months

Interval between Ist booster and 2nd booster dose (ages 50+): 4+ months

More information:
CDC Vaccine Overview
CDC Booster Overview

Moderate or severely immunocompromised people

Age group: 18+ years old

Number of primary vaccine doses: 3

Interval between 1st and 2nd dose: 4 weeks

Interval between 2nd and 3rd dose: 4+ weeks

Number of booster doses: 2

Interval between primary and 1st booster dose: 3+ months

Interval between 1st booster and 2nd booster dose: 4+ months

More information:
CDC Vaccine Overview
CDC Booster Overview

General population

Age group: 18-49 years old

Number of primary vaccine doses: 1

Number of booster doses: 1 (or 2*)

Interval between primary series and 1st booster dose 2+ months

Interval between 1st booster and 2nd mRNA booster dose: 4+ months

More information:
CDC Vaccine Overview
CDC Booster Overview

Moderate or severely immunocompromised people

Age group: 18+ years old

Number of doses: 2 (1 Janssen followed by 1 Pfizer or Moderna mRNA vaccine)

Interval between 1st and 2nd dose: 4 weeks

Number of booster doses: 1

Interval between primary and booster dose: 2+ months

More information:
CDC Vaccine Overview

Age group: 50+ years old

Number of primary vaccine doses: 1

Number of booster doses: 2

Interval between primary series and 1st booster dose 2+ months

Interval between 1st booster and 2nd mRNA booster dose: 4+ months

More information:
CDC Vaccine Overview
CDC Booster Overview

General population

Age group: 18+ years old*

Number of primary vaccine doses: 2

Interval between 1st and 2nd dose: 3-8 weeks

Number of booster doses: Not currently recommended

More information:
CDC Vaccine Overview

Moderate or severely immunocompromised people

Age group: 18+ years old*

Number of primary vaccine doses: 2

Interval between 1st and 2nd dose: 3 weeks

Number of booster doses: Not currently recommended

More information:
CDC Vaccine Overview

Promote health and wellness in your community or workplace

We're here to support your organization's on‐site clinic needs. We would be happy to conduct an on‐site vaccine clinic for your organization or community.

Clinic facts and requirements

Ready to request an off-site vaccine clinic for your business or organization?

Harveys vaccine FAQs

    The CDC is expressing a clinical preference for individuals to receive an mRNA COVID-19 vaccine (Pfizer-BioNTech or Moderna) over Johnson & Johnson’s COVID-19 vaccine. This recommendation followed a robust discussion of the latest evidence on vaccine effectiveness, vaccine safety and rare adverse events, and consideration of the U.S. vaccine supply.

    However, ACIP reaffirmed that receiving any vaccine is better than being unvaccinated. Individuals who are unable or unwilling to receive an mRNA vaccine will continue to have access to Johnson & Johnson’s COVID-19 vaccine.


    Individuals age 12+ are eligible to receive the Pfizer-BioNTech COVID-19 vaccine booster if they completed the Pfizer-BioNTech vaccine series 5 months ago.

    Adults 18 years and older can get any of the COVID-19 vaccine boosters authorized in the United States as long as they completed the Pfizer-BioNTech or Moderna vaccine series 5 months ago, or received the single dose Johnson & Johnson vaccine 2 months ago.


    Individuals age 12+ are eligible to receive the Pfizer-BioNTech COVID-19 vaccine booster if they completed the Pfizer-BioNTech vaccine series 5 months ago.

    If you are 18 and older, you may choose any of the three available COVID-19 vaccines in the United States as a booster shot. Some people may prefer the vaccine type that they originally received, and others may prefer to get a different booster. CDC’s recommendations now allow for this type of mix and match dosing for booster shots.
    Learn more


    With many children back in school and participating in extracurricular activities, COVID-19 vaccination among children ages 5 through 11 years is critical to preventing infection and possible severe disease, as well as reducing the spread of COVID-19. There are approximately 28 million children between the ages of 5 and 11 in the United States, and there have been nearly 2 million cases of COVID-19 within this age group during the pandemic. While fewer children have been sick with COVID-19 compared to adults, children can be infected with the virus, and there is no way to tell in advance if a child will get a severe or mild case. Some children have developed a rare but serious disease that is linked to COVID-19 called multisystem inflammatory syndrome (MIS-C).


    Based on data from the clinical trial, children may have some side effects from COVID-19 vaccination, which are normal signs that their body is building protection. These side effects may affect your child’s ability to do daily activities, but they should go away in a few days. Serious side effects are rare but may occur.


    Select Harveys Pharmacy locations will be offering the Pfizer-BioNTech COVID-19 vaccine for ages 5 to 11. Click here to view our store list.


    As opposed to many medications, vaccine dosages are based on age and not size or weight. If a child turns from 11 to 12 years of age in between their first and second dose, they should receive the age- appropriate dose at the time of administration.


    The Pfizer-BioNTech Vaccine for children ages 5 through 11 has the same active ingredients as the vaccine given to adults and adolescents. The Pfizer-BioNTech Vaccine that is given to adults and adolescents cannot be used for children ages 5 through 11 years. Children ages 5 through 11 will receive an age-appropriate dose that is one third of what adolescents and adults receive. Smaller needles, designed specifically for children, are used for children ages 5 through 11 years. COVID-19 vaccine dosage does not vary by patient weight but by age on the day of vaccination. Children are still required to get two doses three weeks apart to be considered fully vaccinated.


    No. There is no evidence that any vaccines, including COVID-19 vaccines, can cause female or male fertility problems.


    Yes, if a patient is eligible, both flu and COVID-19 vaccines can be administered at the same visit, as recommended by CDC and ACIP. In addition to flu vaccine, COVID-19 vaccine can be given with other vaccines as well.


    Yes, COVID-19 vaccines are available for everyone at no cost, including the Pfizer-BioNTech Vaccine for children ages 5 through 11 years. COVID-19 vaccines will continue to be given to all eligible people living in the United States, regardless of insurance or immigration status.


    Yes, all vaccine recipients, including children ages 5 through 11 years, will receive a CDC vaccination card upon initial vaccination.


    Certain individuals who are moderately to severely immunocompromised may not build enough (or any) protection when they first get a vaccination. When this happens, getting another dose of the vaccine can sometimes help them build more protection against the disease. CDC recommends moderately to severely immunocompromised people consider receiving an additional (third) dose of an mRNA COVID-19 vaccine (Pfizer-BioNTech or Moderna) at least 28 days after the completion of the initial 2-dose mRNA COVID-19 vaccine series.

    In contrast, a “booster dose” refers to another dose of a vaccine that is given to someone who built enough protection after vaccination, but then that protection decreased over time (this is called waning immunity).


    For many who have completed their primary series with Pfizer-BioNTech vaccine, the benefits of getting a booster shot outweigh the known and potential risks. So far, reactions reported after the third PfizerBioNTech shot were similar to that of the 2-shot primary series. Fatigue and pain at the injection site were the most commonly reported side effects, and overall, most side effects were mild to moderate. However, as with the 2-shot primary series, serious side effects are rare, but may occur.


    You can walk-in or schedule an appointment for your second dose Moderna or Pfizer vaccine even if you received your first dose Moderna or Pfizer vaccine at a different location.


    As of August 23, 2021, the FDA has issued full approval of the Pfizer-BioNTech vaccine for ages 16+. The FDA has rigorous scientific and regulatory processes in place to facilitate development and ensure the safety, effectiveness and quality of COVID-19 vaccines. Other COVID-19 vaccines are in development and will be reviewed by the FDA under EUA. Find the current status of the vaccine approvals and EUAs.


    Yes, the additional dose is available at no cost to any eligible patient either through insurance or a federal program for the uninsured.


    Please visit the CDC's page on variants for more information.


    Harveys will be administering the Pfizer and Moderna vaccine. The type of vaccine will vary by state. Click to learn more about each vaccine, the Moderna Vaccine Fact Sheet and Pfizer Vaccine Fact Sheet.


    The U.S. vaccine safety system ensures that all vaccines are as safe as possible. Safety is a top priority while federal partners work to make this and other COVID-19 vaccines available.

    https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety.html


    The CDC and FDA encourage the public to report possible side effects (called adverse events) to the Vaccine Adverse Event Reporting System (VAERS). This national system collects these data to look for adverse events that are unexpected, appear to happen more often than expected, or have unusual patterns of occurrence. Learn about the difference between a vaccine side effect and an adverse event. Reports to VAERS help the CDC monitor the safety of vaccines. Safety is a top priority. Healthcare providers will be required to report certain adverse events following vaccination to VAERS. Healthcare providers also have to adhere to any revised safety reporting requirements according to FDA’s conditions of authorized use throughout the duration of any Emergency Use Authorization; these requirements would be posted on FDA’s website.

    The CDC is also implementing a new smartphone-based tool called v-safe to check-in on people’s health after they receive a COVID-19 vaccine. When you receive your vaccine, you should also receive a v-safe information sheet telling you how to enroll in v-safe. If you enroll, you will receive regular text messages directing you to surveys where you can report any problems or adverse reactions you have after receiving a COVID-19 vaccine.

    V-Safe information sheet
    V-Safe information poster


    COVID-19 vaccines help our bodies develop immunity to the virus that causes COVID-19 without us having to get the illness. Different types of vaccines work in different ways to offer protection, but with all types of vaccines, the body is left with a supply of “memory” T-lymphocytes as well as B-lymphocytes that will remember how to fight that virus in the future. It typically takes a few weeks for the body to produce T-lymphocytes and B-lymphocytes after vaccination. Therefore, it is possible that a person could be infected with the virus that causes COVID-19 just before or just after vaccination and then get sick because the vaccine did not have enough time to provide protection. Sometimes after vaccination, the process of building immunity can cause symptoms, such as fever. These symptoms are normal and are a sign that the body is building immunity.

    https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/how-they-work.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Fvaccines%2Fabout-vaccines%2Fhow-they-work.html


    Vaccine doses will be given to the American people at no cost. The Federal Bureau of Investigation (FBI), Department of Health and Human Services Office of Inspector General (HHS-OIG), and Centers for Medicare & Medicaid Services (CMS) are warning the public about several emerging fraud schemes related to COVID-19 vaccines. If you believe you have been the victim of a COVID-19 fraud, immediately report it to the FBI (ic3.gov, tips.fbi.gov, or 1-800-CALL-FBI) or HHS OIG (tips.hhs.gov or 1-800-HHS-TIPS)


    An N95 FFR is a type of respirator which removes particles from the air that are breathed through it. These respirators filter out at least 95% of very small (0.3 micron) particles. N95 FFRs are capable of filtering out all types of particles, including bacteria and viruses.



    CDC clarified an existing recommendation that people who are moderately or severely immunocompromised—and who receive an mRNA (Pfizer-BioNTech or Moderna) vaccine—receive 4 doses total (a primary series of 3 doses, plus 1 booster dose). In addition, CDC now recommends that people who are moderately or severely immunocompromised—who received the 3-dose primary mRNA COVID-19 vaccine series—receive their booster dose at least 3 months (instead of at least 5 months) after the last primary dose.


    CDC also now recommends that people who are moderately or severely immunocompromised—who received a single J&J/Janssen COVID-19 vaccine primary series—receive a total of three vaccine doses: 1 J&J/Janssen dose, followed by 1 additional mRNA dose, then 1 booster dose. mRNA vaccines are preferred for the booster dose.


    Four doses total. A primary series of 3 doses, plus 1 booster dose. In terms of timing:

    For the Pfizer-BioNTech COVID-19 vaccine, the second dose for people who are moderately or severely immunocompromised is given 21 days (3 weeks) after the first dose, the third dose is given at least 28 days (4 weeks) after the second dose, and the fourth dose (booster dose) is now recommended to be given at least 3 months after the third dose.


    For the Moderna COVID-19 vaccine, the second dose for people who are moderately or severely immunocompromised is given 28 days after the first dose, the third dose is given at least 28 days after the second dose, and the fourth dose (booster dose) is now recommended to be given at least 3 months after the third dose.


    Three doses total–1 J&J/Janssen dose, followed by 1 additional mRNA dose, then 1 booster dose. mRNA vaccines are preferred for the booster dose.


    The additional (second) dose is given at least 28 days (4 weeks) after the Janssen dose. The booster dose (third) dose) is given at least 2 months after the additional mRNA dose.


    The additional dose must be an mRNA COVID-19 vaccine, and an mRNA COVID-19 vaccine is preferred for the booster dose due to concerns about an increased risk for thrombosis with thrombocytopenia syndrome (TTS) when using the Janssen vaccine. TTS is a rare but serious adverse event that causes blood clots or issues with clotting.


Find your nearest pharmacy.

Looking for a location near you? Find a Harveys pharmacy in your area.

One moment, please